Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?

All NewsApril 28, 2025

Revolution Medicines shared Phase 1 data showing zoldonrasib’s acceptable safety profile in KRAS G12D mutant solid tumors at AACR 2025.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent